Study Summary
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy
Want to learn more about this trial?
Request More InfoInterventions
TecartusDRUG
Tecartus is a CD19 directed CAR T-cell therapy that utilizes CD28 costimulatory and CD3 zeta stimulatory domains. Tecartus is manufactured from purified autologous T-cells via retroviral transduction with a median time to product release of 13 days.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Moffitt Cancer Center | Tampa | Florida | United States |